JP2021512140A5 - - Google Patents
Info
- Publication number
- JP2021512140A5 JP2021512140A5 JP2020558858A JP2020558858A JP2021512140A5 JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5 JP 2020558858 A JP2020558858 A JP 2020558858A JP 2020558858 A JP2020558858 A JP 2020558858A JP 2021512140 A5 JP2021512140 A5 JP 2021512140A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methoxyquinoline
- ethylpiperazine
- methylureido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023149903A JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862615848P | 2018-01-10 | 2018-01-10 | |
| US62/615,848 | 2018-01-10 | ||
| PCT/US2019/012886 WO2019139977A1 (en) | 2018-01-10 | 2019-01-09 | Combination therapies for the treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149903A Division JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512140A JP2021512140A (ja) | 2021-05-13 |
| JP2021512140A5 true JP2021512140A5 (cg-RX-API-DMAC10.html) | 2022-01-18 |
| JP7352569B2 JP7352569B2 (ja) | 2023-09-28 |
Family
ID=65411938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020558858A Active JP7352569B2 (ja) | 2018-01-10 | 2019-01-09 | 肝細胞癌の治療のための併用療法 |
| JP2023149903A Active JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023149903A Active JP7665700B2 (ja) | 2018-01-10 | 2023-09-15 | 肝細胞癌の治療のための併用療法 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023533903A (ja) * | 2020-05-15 | 2023-08-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Fgfr4阻害剤の経口製剤によるがんの治療方法 |
| KR20250003965A (ko) | 2022-05-30 | 2025-01-07 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 암 치료용 약학적 조합 및 약학적 조성물 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| HUE025742T2 (hu) | 2003-12-25 | 2016-04-28 | Eisai R&D Man Co Ltd | 4-(3-klór-4-(ciklopropilamino-karbonil)aminofenoxi)-7-metoxi-6-kinolin-karboxamid vagy szolvátja sójának kristálya és eljárás elõállításukra |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| CA2704000C (en) * | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| MX2014009303A (es) * | 2012-01-31 | 2014-10-14 | Novartis Ag | Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer. |
| CN105338977B (zh) * | 2013-06-26 | 2018-10-16 | 卫材R&D管理有限公司 | 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途 |
| SG11201602069WA (en) | 2013-10-18 | 2016-04-28 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| US10736900B2 (en) * | 2014-03-26 | 2020-08-11 | Astex Therapeutics Ltd | Combinations of an FGFR inhibitor and an IGF1R inhibitor |
| US20160089365A1 (en) * | 2014-09-25 | 2016-03-31 | Eisai R&D Management Co., Ltd. | Immunostimulatory compound |
| CN107660200B (zh) | 2015-04-14 | 2022-01-11 | 卫材R&D管理有限公司 | 结晶fgfr4抑制剂化合物和其用途 |
| CN107304188A (zh) * | 2016-04-20 | 2017-10-31 | 成都融科博海科技有限公司 | 一种氘代激酶选择性抑制剂及其应用 |
| JP7372740B2 (ja) * | 2016-05-10 | 2023-11-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ |
-
2019
- 2019-01-09 KR KR1020257016389A patent/KR20250073570A/ko active Pending
- 2019-01-09 CA CA3088292A patent/CA3088292A1/en active Pending
- 2019-01-09 EP EP19705261.6A patent/EP3737377B1/en active Active
- 2019-01-09 WO PCT/US2019/012886 patent/WO2019139977A1/en not_active Ceased
- 2019-01-09 SG SG11202006617RA patent/SG11202006617RA/en unknown
- 2019-01-09 US US16/961,292 patent/US11833119B2/en active Active
- 2019-01-09 EP EP25207224.4A patent/EP4667005A3/en active Pending
- 2019-01-09 AU AU2019206480A patent/AU2019206480A1/en not_active Abandoned
- 2019-01-09 BR BR112020014112-7A patent/BR112020014112A2/pt not_active IP Right Cessation
- 2019-01-09 MX MX2020007375A patent/MX2020007375A/es unknown
- 2019-01-09 CN CN201980015321.XA patent/CN111787922A/zh active Pending
- 2019-01-09 KR KR1020207022999A patent/KR102811519B1/ko active Active
- 2019-01-09 JP JP2020558858A patent/JP7352569B2/ja active Active
- 2019-01-09 MA MA051570A patent/MA51570A/fr unknown
-
2020
- 2020-07-12 IL IL275981A patent/IL275981A/en unknown
-
2023
- 2023-09-15 JP JP2023149903A patent/JP7665700B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019059760A5 (cg-RX-API-DMAC10.html) | ||
| ES2393211T3 (es) | Uso de 2-aminotetralinas sustituidas para la fabricación de un medicamento para la prevención, alivio y/o tratamiento de diversos tipos de dolor | |
| ES2654787T3 (es) | Formulación farmacéutica disponible por vía oral adecuada para la gestión mejorada de trastornos del movimiento | |
| JP2024540183A5 (cg-RX-API-DMAC10.html) | ||
| JP2004525179A5 (cg-RX-API-DMAC10.html) | ||
| JP2021152008A5 (cg-RX-API-DMAC10.html) | ||
| JP2012162581A (ja) | 経口治療用化合物の供給系 | |
| WO2002092088A3 (en) | Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts | |
| JP2006508953A5 (cg-RX-API-DMAC10.html) | ||
| JP2017528507A5 (cg-RX-API-DMAC10.html) | ||
| CY1119663T1 (el) | Φαρμακευτικη μορφη δοσολογιας για απο του στοματος χορηγηση ενος αναστολεα της οικογενειας bcl-2 | |
| JP2012532874A5 (cg-RX-API-DMAC10.html) | ||
| JP2018168191A5 (cg-RX-API-DMAC10.html) | ||
| JP2015528471A5 (cg-RX-API-DMAC10.html) | ||
| JP2017530983A5 (cg-RX-API-DMAC10.html) | ||
| JP2006516570A5 (cg-RX-API-DMAC10.html) | ||
| JP2014502979A5 (cg-RX-API-DMAC10.html) | ||
| JP2017537899A5 (cg-RX-API-DMAC10.html) | ||
| ES2966929T3 (es) | Tratamiento de trastornos del movimiento | |
| JP2019515909A5 (cg-RX-API-DMAC10.html) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2019536812A5 (cg-RX-API-DMAC10.html) | ||
| JP2014505107A5 (cg-RX-API-DMAC10.html) | ||
| JP2018537507A5 (cg-RX-API-DMAC10.html) | ||
| DK1427396T3 (da) | Doseringsformer med forlænget frigivelse af aktivt indholdsstof |